elacestrant CAS: 722533-56-4 CAS: 1349723-93-8

CAS NO: 1349723-93-8
Elacestrant CAS: 722533-56-4: An Impressive Product with Potential
Description Review
Description
Elacestrant CAS: 722533-56-4 is a groundbreaking compound that has attracted considerable attention in recent years. In this article, we will explore the top 10 popular keywords associated with Elacestrant according to Google. Additionally, we will delve into its mechanism of action, potential impacts, side effects, contraindications, and provide a concise summary of this product.
Keywords:
Elacestrant breast cancer
SERD therapy
Targeted breast cancer treatment
Estrogen receptor modulator
Selective estrogen receptor degrader
Elacestrant clinical trials
Elacestrant efficacy
Elacestrant safety profile
Oral SERD
Potential ER+ breast cancer therapy
Mechanism of Action:
Elacestrant acts as a selective estrogen receptor modulator, specifically targeting estrogen receptor-positive (ER+) breast cancer. By binding to the estrogen receptor, it disrupts the action of estrogen, an essential hormone for the growth of ER+ breast cancer cells. This mechanism inhibits cancer cell growth and potentially leads to tumor regression.
Potential Impacts:
Elacestrant offers promising potential as a targeted therapy for ER+ breast cancer. It aims to suppress tumor growth and improve patient outcomes by impeding estrogen signaling, which fuels cancer proliferation. Early studies indicate its ability to halt tumor progression and potentially overcome resistance to other treatments.
Side Effects:
Like any medical intervention, elacestrant may have associated side effects. Commonly observed side effects may include fatigue, mild nausea, musculoskeletal discomfort, and hot flashes. However, it's crucial to remember that side effects can vary among individuals, and consulting a healthcare professional is important for personalized guidance.
Contraindications:
Elacestrant may not be suitable for individuals with known allergies to the drug or its components. It may also have restrictions for patients with severe liver disease or impairment. As with any medication, it is vital to discuss existing medical conditions and potential drug interactions with a healthcare professional before initiating elacestrant therapy.
Summary:
Elacestrant CAS: 722533-56-4 is an intriguing product under development for ER+ breast cancer treatment. Its mechanism of action involves targeting the estrogen receptor and impeding estrogen signaling, resulting in decreased cancer cell growth. While early studies show significant potential, further research is required to establish its long-term efficacy and safety profile.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us